Discounted Cash Flow
Treace Medical Concepts, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $39.4m | $-4.3m | $-8.9m | -10.8% | — |
| 2020 | $57.4m (45.5%) | $-3.7m (14.0%) | $-5.6m (37.4%) | -6.4% (40.9%) | $-0.12 |
| 2021 | $94.4m (64.6%) | $-20.6m (-460.3%) | $-19.9m (-257.7%) | -21.8% (-240.4%) | $-0.43 (-258.3%) |
| 2022 | $141.8m (50.2%) | $-42.8m (-108.3%) | $-45.5m (-128.6%) | -30.2% (-38.7%) | $-0.77 (-79.1%) |
| 2023 | $187.1m (31.9%) | $-49.5m (-15.7%) | $-46.0m (-1.2%) | -26.5% (12.3%) | $-0.81 (-5.2%) |
| 2024 | $209.4m (11.9%) | $-55.7m (-12.6%) | $-48.8m (-5.9%) | -26.6% (-0.6%) | $-0.90 (-11.1%) |
| 2025 | $212.7m (1.6%) | $-59.0m (-5.8%) | $-29.5m (39.5%) | -27.7% (-4.2%) | $-0.93 (-3.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.